Valuation: Valneva SE

Market Cap 493M 550M 454M 413M 781M 51.54B 803M 5.44B 2.17B 27.61B 2.06B 2.02B 87.29B P/E 2026 *
-5.95x
P/E 2027 * 9.38x
Enterprise Value 627M 699M 578M 525M 993M 65.56B 1.02B 6.92B 2.76B 35.13B 2.62B 2.57B 111B EV / Sales 2026 *
4.16x
EV / Sales 2027 * 1.96x
Free-Float
89.58%
Yield 2026 *
-
Yield 2027 * -
1 day+0.12%
1 week+8.96%
Current month+5.63%
1 month+2.29%
3 months+14.34%
6 months+7.96%
Current year-30.31%
1 week 2.45
Extreme 2.453
2.75
1 month 2.33
Extreme 2.326
2.75
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.15
3 years 1.73
Extreme 1.726
6.54
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 2021-07-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 2023-12-19
Director/Board Member 75 2013-03-06
Chairman 65 2023-12-19
Date Insider Type Main position Quantity % Market Cap. Importance
1/27/26 Sell

Chief Technology Officer

11,800 0.0069%
1/26/26 Sell

Chief Financial Officer

11,800 0.0069%
1/19/26 Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
+0.12%+8.96%-29.17%-58.91% 552M
+0.01%+8.40%+58.48%+69.01% 68.22B
+1.22%+10.23%+18.35%+87.67% 59.82B
+0.24%+1.97%+24.62%+94.87% 56.07B
+1.60%+17.36%+32.51%+123.69% 47.67B
-1.32%+6.47%+30.74%+43.37% 45.95B
-3.54%+2.60%+216.44%+864.34% 43.29B
-3.33%+5.73%+23.28%+47.32% 35.66B
-2.19%-3.16%+93.83%+63.14% 34.73B
+2.92%+9.31%-37.01%+410.20% 25.47B
Average -0.43%+5.70%+43.21%+174.47% 42B
Weighted average by Cap. -0.41%+5.41%+52.53%+179.37%

Financials

2026 *2027 *
Net sales 151M 168M 139M 126M 239M 15.77B 246M 1.66B 663M 8.45B 631M 618M 26.71B 283M 316M 261M 237M 449M 29.62B 461M 3.13B 1.25B 15.87B 1.19B 1.16B 50.16B
Net income -81.35M -90.71M -74.97M -68.09M -129M -8.51B -132M -898M -358M -4.56B -340M -333M -14.41B 53.02M 59.12M 48.87M 44.38M 83.99M 5.54B 86.33M 585M 233M 2.97B 222M 217M 9.39B
Net Debt 134M 150M 124M 112M 213M 14.03B 218M 1.48B 590M 7.52B 561M 550M 23.76B 62.86M 70.09M 57.93M 52.61M 99.57M 6.57B 102M 694M 276M 3.52B 263M 257M 11.13B
Projected Income Statement - Annual - Valneva SE
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
26-11-10 €2.591 +0.12% 917,479
26-11-09 €2.588 +3.44% 718,550
26-11-06 €2.502 -2.11% 242,738
26-11-05 €2.556 +0.95% 440,201
26-11-04 €2.532 +2.10% 435,408
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Valneva SE
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.591EUR
Average target price
6.200EUR
Spread / Average Target
+139.29%